Carisma Therapeutics names new chief scientific officer
26 April 2022 -

Carisma Therapeutics Inc., a US-based clinical stage biopharmaceutical company, announced on Monday that it has named Michael Klichinsky, PharmD, PhD as its new chief scientific officer.

Dr Klichinsky co-founded the company in 2016 subsequent to his foundational work at the University of Pennsylvania that led to the development of the company's chimeric antigen receptor macrophage (CAR-M) technology. He holds his PhD in Pharmacology from the Perelman School of Medicine at the University of Pennsylvania.

Steven Kelly, Carisma president and chief executive officer, said, 'The entire Carisma team is thrilled and honoured to have Mike assume the role of chief scientific officer on behalf of the company and to continue driving our novel cell therapy technology. Working alongside Mike for nearly five years, I continue to be impressed by his expertise and passion for the work that we do – and am confident that through his leadership of our organisation's research efforts, we will continue to see the benefits and impact of his thoughtful and critical approach to engineered cell therapies unfold.'